Correspondence 0001213900-24-055130 from NewcelX Ltd. (NCEL)
NewcelX Ltd.
Date: June 24, 2024 · CIK: 0001783036 · Accession: 0001213900-24-055130
AI Filing Summary & Sentiment
Reasoning
Letter
VIA EDGAR Securities and Exchange Commission Division of Corporation Finance United States Securities and Exchange Commission Washington, D.C. 20549 Re: NLS Pharmaceutics Ltd. (CIK: 0001783036) Registration Statement on Form F-1 (File No. 333- 279806) (the “Registration Statement”) Request for Acceleration of Effective Date
Dear Sir or Madam:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Securities Act”), NLS Pharmaceutics Ltd. (the “Registrant”) hereby requests that the effective date of the above-referenced Registration Statement be accelerated so that it will be declared effective on June 25, 2024 at 4:15 p.m., Eastern Time, or as soon as practicable thereafter.
The Registrant understands that the Securities and Exchange Commission will consider this request for acceleration of the effective date of the Registration Statement as a confirmation of the fact that the Registrant is aware of its responsibilities under the Securities Act as they relate to the proposed public offering of the securities specified in the Registration Statement.
The Registrant respectfully requests that it be notified of such effectiveness by a telephone call to Howard E. Berkenblit, Esq. of Sullivan & Worcester LLP at (617) 338-2979 and that such effectiveness also be confirmed in writing.
Very truly yours,
NLS PHARMACEUTICS LTD.
Show Raw Text
CORRESP
1
filename1.htm
NLS Pharmaceutics Ltd.
The Circle 6
8058 Zurich, Switzerland
June 24, 2024
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
United States Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Re: NLS Pharmaceutics Ltd. (CIK: 0001783036)
Registration Statement on Form F-1 (File No. 333-
279806) (the “Registration Statement”)
Request for Acceleration of Effective Date
Dear Sir or Madam:
Pursuant to Rule 461 under
the Securities Act of 1933, as amended (the “Securities Act”), NLS Pharmaceutics Ltd. (the “Registrant”) hereby
requests that the effective date of the above-referenced Registration Statement be accelerated so that it will be declared effective on
June 25, 2024 at 4:15 p.m., Eastern Time, or as soon as practicable thereafter.
The Registrant understands that
the Securities and Exchange Commission will consider this request for acceleration of the effective date of the Registration Statement
as a confirmation of the fact that the Registrant is aware of its responsibilities under the Securities Act as they relate to the proposed
public offering of the securities specified in the Registration Statement.
The Registrant respectfully requests
that it be notified of such effectiveness by a telephone call to Howard E. Berkenblit, Esq. of Sullivan & Worcester LLP at (617) 338-2979
and that such effectiveness also be confirmed in writing.
Very truly yours,
NLS PHARMACEUTICS LTD.
By:
/s/ Alexander C. Zwyer
Alexander C. Zwyer, Chief Executive Officer